

Tralyte +health

Electrolyte Insight on Demand

Tralyte Health Debuts Prototype Electrolyte Monitor for Home Use

Novel Calcium Monitor Draws Significant Attention During International Hypoparathyroidism Conference Debut

FOR IMMEDIATE RELEASE

Richmond, VA — September 23, 2026 — On the first anniversary of its founding, metabolic diagnostics startup [Tralyte Health](#) announced the development of the prototype for TralyteCare, a novel, patient-operated calcium testing system designed for home and point-of-care use in testing blood and urine. The investigational device is intended to measure total calcium in small capillary whole blood and urine samples, delivering results in approximately 15 minutes.

TralyteCare was first unveiled to patients at the [International HypoPARA Conference 2026](#) in Phoenix on Friday. The unveiling generated significant interest from patients, advocacy leaders, clinicians, and pharmaceutical companies attending the conference. The Tralyte co-founders were featured on Sunday in a dedicated presentation and audience Q&A session, during which attendees overwhelmingly indicated support for making home calcium monitoring available to patients. The Tralyte exhibit saw sustained traffic throughout the event, and multiple attendees reported traveling to the conference specifically to see the device demonstration.

Today, all quantitative calcium testing requires a trained technician performing a venous blood draw in a centralized laboratory. TralyteCare is intended to be the first patient-operated system to provide quantitative calcium measurements in the home or point-of-care setting, offering the potential for more timely biochemical insight during symptomatic episodes or other clinically indicated situations such as dose calibration, intercurrent illness, or clinically meaningful life changes.

The device was conceived in response to the substantial clinical need faced by hypoparathyroidism patients, who often experience unpredictable calcium instability and the limitations of current diagnostic pathways, which can delay biochemical confirmation during symptomatic episodes.

“For the first time, we are demonstrating a path toward patient-operated calcium testing outside of a laboratory,” said [Jay Atkinson, co-founder and CEO of Tralyte Health](#). “Patients

Tralyte +health

Electrolyte Insight on Demand

have told us they need access to timely calcium information, and the response at the International HypoPARA Conference reinforced that demand.”

TralyteCare is an investigational, prescription-use test system designed to provide quantitative total calcium measurements using small capillary blood and urine samples collected in the home or point-of-care setting. The system is intended to support patients and clinicians in evaluating biochemical status during symptomatic episodes or other clinically indicated situations. TralyteCare has not been cleared or approved by FDA, and its safety and effectiveness have not yet been established via validation studies.

About Tralyte Health

Tralyte Health is developing a diagnostics platform to take metabolic testing out of the lab and into the home. While the platform will ultimately expand to additional electrolytes, the company is entering the market through calcium. Tralyte is developing a handheld, home-use calcium sensor designed for people living with hypoparathyroidism, a debilitating rare disease that often requires frequent testing — sometimes daily — yet currently offers no practical way for patients to check their calcium levels in blood and urine at home. Tralyte Health aims to make timely biochemical insight more accessible to patients and clinicians when it is needed most.

Tralyte Health originated from academic research conducted at [Virginia Commonwealth University \(VCU\)](#) and is supported by Virginia’s innovation ecosystem, including [Activation Capital](#) and the [Virginia Innovation Partnership Corporation \(VIPC\)](#). TralyteCare is in development and is not yet cleared or approved by FDA.

Learn more at www.tralytehealth.com.

Media Contact

Laurie Atkinson

Co-founder & CCO

Tralyte Health

laurie@tralytehealth.com

301.523.3165